LAUSR

Cannabis‐based products for medicinal use, also referred to as cannabinoid‐containing products, particularly those containing cannabidiol as the primary active constituent, have shown to be a possible alternative in treating various health conditions in companion animals. Thus, this systematic review aims to synthesise and analyse the available data on the efficacy/effectiveness and safety of cannabis‐based products for medicinal use in dogs and cats to assist in clinical decision‐making.A systematic review was conducted across PubMed, LILACS, Scopus, and Google Scholar from February 2014 to February 2024. The search strategy included both MeSH terms and free‐text keywords related to medical cannabis, including Medical Marijuana, Cannabis and Cannabaceae, combined with terms referring to domestic cats and dogs. Additionally, title/abstract keywords, including Cannab (as a truncated term), were used to retrieve literature on cannabinoids and their therapeutic applications.Twenty‐two articles were identified examining cannabidiol‐based formulations for osteoarthritis, epilepsy, atopic dermatitis, postsurgical pain, and behavioural issues. Cannabis‐based products for medicinal use with cannabidiol as the primary active constituent demonstrated improvements in pain, behaviour, and seizures, with no serious adverse events. However, research on their use in cats is limited to two studies.While promising, the long‐term efficacy/effectiveness, optimal dosages, and safety of cannabis‐based products for medicinal use remain unclear. Further studies are needed to confirm their therapeutic potential and ensure safe veterinary use.